48
Participants
Start Date
July 28, 2016
Primary Completion Date
April 26, 2018
Study Completion Date
April 26, 2018
Vamorolone 0.25 mg/day/day
Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Vamorolone 0.75 mg/day/day
Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Vamorolone 2.0 mg/day/day
Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Vamorolone 6.0 mg/day/day
Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Duke University, Durham
University of Florida, Gainesville
Nemours Children's Hospital, Orlando
Queen Silvia Children's Hospital, Gothenburg
Schneider Children's Medical Center, Petah Tikva
Ann & Robert H. Lurie Children's Hospital, Chicago
University of Texas Southwestern Medical Center, Dallas
University of California Davis, Davis
Royal Children's Hospital, Melbourne
Sydney Children's Hospital, Westmead
Alberta Children's Hospital, Calgary
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
University of Pittsburgh
OTHER
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Cooperative International Neuromuscular Research Group
NETWORK
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
ReveraGen BioPharma, Inc.
INDUSTRY